EUCTR2010-019706-16-IT进行中（未招募）不适用
A randomized, double blind, placebo controlled, parallel groups, pilot study to assess the effects of two new nail lacquers, cyclosporine 5% and calcipotriol 0.005%, in the treatment of nail psoriasis - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- POLICHEM
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent before starting any study related procedures • Patients aged = 18 and = 80 years old • Males or females • Outpatients • Patients with established clinical diagnosis of mild to moderate psoriasis (BSA involvement = 10% or PASI = 10) having nail psoriasis (fingernails) of the nail matrix and /or the nail bed affecting at least one nail • Presence of at least one clinical sign of nail psoriasis of the matrix (pitting, leukonychia, red spots in lunula, nail plate crumbling) and/or of the nail bed (salmon patch, onycholysis, hyperkeratosis and splinter hemorrhage) in at least one nail
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinical diagnosis of psoriasis for less than six months •Use of any systemic treatment for psoriasis during the last six months before the screening visit until the end of the study •Use of photochemotheraphy (phototherapy is permitted) or other forms of radiotherapy during the last four weeks before the screening visit until the end of the study •Positive mycology findings (KOH evaluation or culture) obtained in the three months before the screening visit or positive KOH evaluated at the screening visit •Patients using nail polish or other nail cosmetic products during last 72 hours prior to study drug application until the end of the study •Use of the following therapies for any reason during last three months before the screening visit until the end of the study: immunosuppressive, chemotherapy and corticosteroids •Assumption of Vitamin D or its analogues for any reason during the last three months before the screening visit •Patients with history of cardiovascular, renal, neurologic, liver, immunologic or endocrine dysfunction if they are clinically significant A clinically significant disease is defined as one which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient’s ability to participate in the study •Patients with a recent history (< 1 year) of myocardial infarction and/or (< 3 years) of heart failure or patients with any cardiac arrhythmia requiring drug therapy •History of nephropathy or serum creatinine, urate or potassium levels more than twice above the upper limit of reference range •History of viral hepatitis B or C or AST, ALT and ?GT levels more than twice above the upper limit of reference range •History of previous or current malignancy in particular lymphoma, melanoma and basal cell carcinoma •History of allergic reactions to Cyclosporine or P-3072 excipients •History of allergic reactions to Calcipotriol or P-3073 excipients •Patients unable to understand the procedures and purposes of the study •Patients unable or unwilling to accept and meet study requirements •Use of an investigational drug or participation in an investigational study within 30 days prior to application of study medication •Alcohol or substance abuse •AIDS symptoms or any other immunodeficiency Additional exclusion criteria for females only: •Breast-feeding patients •Positive urine pregnancy test at screening (performed to all females of child bearing potential or being in non surgical post-menopause for less than 1 year) •Female of childbearing potential having unprotected sexual intercourse with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy at least 6 months prior to drug application) within 14 days prior to study drug application. Acceptable methods of contraception are the following: condom, diaphragm, intrauterine contraceptive device (placed at least 4 weeks prior to study drug application), pill + condom Exclusion criteria during the study: •Any systemic treatment for psoriasis •Any topical product on nails (cosmetic or local treatment for nail psoriasis) •Use of the following therapies: immunosuppressive, chemotherapy, corticosteroids, vitamin D or its analogues •Evidence of pregnancy will lead the treatment to be stopped and pregnancy outcome followed up until delivery
研究者
相似试验
招募中
3 期
Evaluation of probiotic Akkermansia Muciniphila strain in patients with IBS.CTRI/2024/03/064023Vidya Herbs Pvt LTD
进行中（未招募）
1 期
Investigate the safety and efficacy of study drug ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have failed to other treatments.Moderate to Severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-003558-26-DEABIVAX232
招募中
不适用
Effect of herbal extract on reducing body fat in healthy adultsCTRI/2022/10/046429Sangol Farm
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors - Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy (PALLAS)MedDRA version: 13.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2010-019791-73-DKSanofi-aventis recherche & développement10,800
进行中（未招募）
1 期
A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors - Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy (PALLAS)MedDRA version: 14.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2010-019791-73-NLSanofi-aventis recherche & développement10,800